MedTrace Logo

Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A

NCT01790828 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2015-08-17

Study results available
· View outcomes & findings →

Summary

This study is to describe the safety and efficacy of Xyntha® during the usual care setting.

Conditions

Interventions

DRUG

Xyntha : coagulation factor IIIV (recombinant)

Xyntha will be administered according to physician's discretion.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01790828 on ClinicalTrials.gov